EHMT2-mediated H3K9 mono-methylation and subsequent transcriptional upregulation of the glutamate-cysteine ligase catalytic subunit promotes glutathione biosynthesis and cisplatin resistance, whereas knockdown of EHMT2 gene via shRNA transfection or treatment with the EHMT2 inhibitor UNC0638 can lead to re-sensitivity of resistant HNSCC cells (SAS-CR, OECM-1) to cisplatin in vitro (27). Here, EHMT2 is linked to head and neck squamous cell carcinoma.